Associations with Organ Involvement and Autoantibodies in Systemic Sclerosis: Results from the Canadian Scleroderma Research Group (CSRG)

Vikram Tangri, Carly Hewson, Murray Baron, A. Bonner, Marvin Fritzler, Janet E. Pope

McGill University, Montreal, Canada.
McMaster University, Hamilton, Canada.
University of Calgary, Calgary, Canada.
University of Western Ontario, London, Canada.

DOI: 10.4236/ojra.2013.32017                

Abstract

Objective: Serum from SSc patients was analyzed centrally to determine ANA patterns and extractable nuclear antigens (ENAs) between lcSSc and dcSSc and associations with organ involvement. Methods: 1145 SSc patients had ANA and ENA analyzed by indirect immunofluorescence on HEp-2 substrate at a screening serum dilution of 1/160. Most ENA antibodies [Sm. U1-RNP, Ro52, SS-A/Ro60, topoisomeraseI (Topo1), SS-B/La, chromatin, ribosomal P and Jo1] were measured by laser bead immunoassay; and RNA polymerase III (RNAP) by ELISA. Results: ANA was positive in 95% (same in lcSSc, and dcSSc). Centromere pattern was present in 34%, speckled 22%, nucleolar 18%, homogeneous and speckled (H&S) 16%, multiple nuclear dots 6%. Anti-centromere Ab (ACA) occurred in 46% of lcSSc and 11% of dcSSc (P = 0.0001). ENAs that differed between lcSSc and dcSSc subsets were Topo1 (OR 2.4, P = 0.0001) and RNAP (OR 5.6, P < 0.0001) more common in dcSSc. Overall, 15% had positive Topo1; usually with a H&S pattern (67%); Topo1 was associated with ILD on CXR (OR 2.3; 95% CI 1.5 - 3.5) and HRCT (OR 3.8; 95% CI 1.8 - 8.2). RNAP occurred in 18.5% (35.4% in dcSSc vs. 8.9% in lcSSc). Scleroderma renal crisis (SRC) was 13 times more likely if RNAP positive; P = 0.0001. ACA was only weakly associated with sPAP > 50 mmHg (OR 1.8; 95%CI 1.1 - 3.0). Conclusion: ANA homogeneous pattern alone is rare in SSc; ACA was significantly more common in lcSSc. Many ENAs are equal in lcSSc and dcSSc except RNAP and Topo1. RNAP has the highest OR of SRC. Topo1 is less strongly associated with ILD. Abstract word count: 249, Body word count 1246, Figures 2, Tables 2. Key Messages: 1) 95% of SSc has a positive ANA and ANA patterns in SSc include centromere, nucleolar, and homogeneous and speckled together; 2) Most ENAs are equal in both dcSSc and lcSSc except anti RNA polymerase III and topoisomerase I; 3) RNA polymerase III has the highest association (odds ratio) with scleroderma renal crisis, topoisomerase I is associated with interstitial lung disease; whereas anticentromere was not associated with elevated pulmonary arterial pressures on echocardiogram.

Keywords

Scleroderma; SSc; Systemic Sclerosis; Antibodies; Anticentromere; Topoisomerase I; RNA Polymerase III; Organ Involvement; Scleroderma Renal Crisis; Pulmonary Fibrosis; ILD; ANA; Pulmonary Hypertension

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	E. C. LeRoy, C. Black, R. Fleischmajer, et al., “Scleroderma (Systemic Sclerosis): Classification, Subsets, and Pathogenesis,” Journal of Rheumatology, Vo1. 15, No. 2, 1988, pp. 202-205.
[2]	E. M. Tan, “Antinuclear Antibodies: Diagnostic Markers for Autoimmune Diseases and Probes for Cell Biology,” Advances in Immunology, Vol. 44, 1989, pp. 93-151. doi:10.1016/S0065-2776(08)60641-0
[3]	J. D. Reveille and D. H. Solomon, “Evidence-Based Guidelines for the Use of Immunologic Tests: Anticentromere, Scl-70, and Nucleolar Antibodies,” Arthritis Care & Research, Vol. 49, No. 3, 2003, pp. 399-412. doi:10.1002/art.11113
[4]	M. D. Mayes, J. V. Lacey Jr., J. Beebe-Dimmer, B. W. Gillespie, B. Cooper, T. J. Laing, et al., “Prevalence, Incidence, Survival, and Disease Characteristics of Systemic Sclerosis in a Large US Population,” Arthritis & Rheumatism, Vol. 48, No. 8, 2003, pp. 2246-2255. doi:10.1002/art.11073
[5]	R. J. Allcock, I. Forrest, P. A. Corris, P. R. Crook and I. D. Griffiths, “A Study of the Prevalence of Systemic Sclerosis in Northeast England,” Rheumatology (Oxford), Vol. 43, No. 5, 2004, pp. 596-602.
[6]	J. D. Reveille, M. Fischbach, T. McNearney, et al., “Systemic Sclerosis in 3 US Ethnic Groups: A Comparison of Clinical, Sociodemographic, Serologic, and Immunogenetic Determinants,” Seminars in Arthritis and Rheumatism, Vol. 30, No. 5, 2001, pp. 332-346. doi:10.1053/sarh.2001.20268
[7]	V. Steen, “Autoantibodies in Sytemic Sclerosis,” Seminars in Arthritis and Rheumatism, Vol. 35, No. 1, 2005, pp. 35-42. doi:10.1016/j.semarthrit.2005.03.005
[8]	C. Rigamonti, et al., “Clinical Features and Prognosis of Primary Biliary Cirrhosis Associated with Systemic Sclerosis,” Gut, Vol. 55, No. 3, 2006, pp. 388-394. doi:10.1136/gut.2005.075002
[9]	C. G. Kallenberg, A. A. Wouda, M. H. Hoet and W. J. van Venrooij, “Development of Connective Tissue Disease in Patients Presenting with Raynaud’s Phenomenon: A Six-Year Follow-up with Emphasis on the Predictive Value of Antinuclear Antibodies as Detected by Immunoblotting,” Annals of Rheumatic Diseases, Vol. 477, No. 8, 1988, pp. 634-641. doi:10.1136/ard.47.8.634
[10]	D. Basu and J. D. Reveille, “Anti-scl-70,” Autoimmunity, Vol. 38, No. 1, 2005, pp. 65-72 doi:10.1080/08916930400022947
[11]	R. Hesselstrand, A. Scheja, G. Q. Shen, A. Wiik and A. Akesson, “The Association of Antinuclear Antibodies with Organ Involvement and Survival in Systemic Sclerosis,” Rheumatology (Oxford), Vol. 42, No. 4, 2003, pp. 534-540. doi:10.1093/rheumatology/keg170
[12]	U. A. Walker, et al., “Clinical Risk Assessment of Organ Manifestations in Systemic Sclerosis: A Report from the eULAR Scleroderma Trials and Research Group Database,” Annals of Rheumatic Diseases, Vol. 66, No. 6, 2007, pp. 754-763. doi:10.1136/ard.2006.062901
[13]	G. Spencer-Green, D. Alter and H. G. Welch, “Test Per- formance in Systemic Sclerosis: Anti-Centromere and Anti-Scl-70 antibodies,” The American Journal of Medi- cine, Vol. 103, No. 3, 1997, pp. 242-248. doi:10.1016/S0002-9343(97)00023-5
[14]	M. Kuwana, et al., “Enzyme-Linked Immunosorbent Assay for Detection of Anti-RNA Polymerase III Antibody: Analytical Accuracy and Clinical Associations in Systemic Sclerosis,” Arthritis & Rheumatism, Vol. 52, No. 8, 2005, pp. 2425-2432. doi:10.1002/art.21232
[15]	E. J. Cepeda and J. D. Reveille, “Autoantibodies in Sys- temic Sclerosis and Fibrosing Syndromes: Clinical Indi- cations and Relevance,” Current Opinion in Rheumatol- ogy, Vol. 16, 2004, pp. 723-732. doi:10.1097/01.bor.0000144760.37777.fa
[16]	C. C. Bunn, C. P. Denton, X. Shi-Wen, C. Knight and C. M. Black, “Anti-RNA Polymerases and Other Autoantibody Specificities in Systemic Sclerosis,” Rheumatology, Vol. 37, No. 1, 1998, pp. 15-20. doi:10.1093/rheumatology/37.1.15
[17]	D. Launay, M. Humbert, A. Berezne, V. Cottin, Y. Allanore, L. J. Couderc, O. Bletry, A. Yaici, P. Y. Hatron, L. Mouthon, J. Le Pavec, P. Clerson and E. Hachulla, “Clinical Characteristics and Survival in Systemic Sclerosis-Related Pulmonary Hypertension Associated with Interstitial Lung Disease,” Chest, Vol. 140, No. 4, 2011, pp. 1016-1024. doi:10.1378/chest.10-2473
[18]	F. Boin, S. Franchini, E. Colantuoni, A. Rosen, F. M. Wigley and L. Casciola-Rosen, “Independent Association of Anti-Beta (2)-Glycoprotein I Antibodies with Macrovascular Disease and Mortality in Scleroderma Patients,” Arthritis & Rheumatism, Vol. 60, No. 8, 2009, pp. 2480- 2489. doi:10.1002/art.24684